

For Immediate Release

TSX Exchange Symbol: RVX

Resverlogix Commends Dr. William Cochrane's Induction into the Canadian Medical Hall of Fame

October 26, 2009 (Calgary, AB) — Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) congratulates Dr. William Cochrane, OC, MD, FRCPC, FACP, DABP, Chairman of Resverlogix's Board of Directors, who was recently announced as one of six medical pioneers inducted into the Canadian Medical Hall of Fame. Dr. Cochrane will join 76 Hall of Fame laureates who have been inducted for their work which pushed the boundaries of knowledge to advance human health. Previous appointees include Dr. Frederick Banting and Dr. Charles Best the co-founders of insulin; as well as Dr. Michael Smith for his discovery of site directed mutagenesis and Dr. Jacques Genest a preeminent researcher of the cause and treatment of high blood pressure, to name a few.

Dr. Cochrane was recognized early on as a leader in pediatrics, Dr. Cochrane's career evolved through medical research, medical education, biotechnology and business. A visionary who never gave up, Dr. Cochrane had an extraordinary ability to attract and encourage others to join him in his pursuit for excellence in Canadian medicine. As a pediatrician, Dr. Cochrane was one of the first non-hospital sub-specialists to practice in Ontario. His research interests led to the development of an acetone tolerance test to diagnose glycogen storage disease of the liver (1953) and to the Cochrane (L-leucine) test still in use today to identify a form of hypoglycemia that is sensitive to protein intake (1956).

Deciding to move to Calgary Dr. Cochrane arrived with limited resources, to develop a medical school at the University of Calgary. Attracted by the opportunity to start afresh, he introduced a systems-based approach to teaching medicine and began one of only two three-year MD training programs in North America. Several successful ventures followed including becoming Alberta's Deputy Minister of Health (1973-1974). As President of the University of Calgary (1974-1978) he established Faculties of Humanities and Law. Moving into the realm of business, as Chairman and CEO of Connaught Laboratories (1978-1989), Dr. Cochrane championed a new strategy for the company that focused on genetic engineering. He also sat on 30 Boards of corporations ranging from biotechnology to real estate, in addition to being a dedicated community leader.

Among numerous awards, Dr. Cochrane received the Order of Canada (1989), the Queens Golden Jubilee Award (2002), the Alberta Order of Excellence (2007) and was elected to the Biotechnology Hall of Fame by the BioAlberta Association (2008). He was named one of 100 Alberta Physicians of the Century (2005) and has received four honorary doctorates. His interest in helping First Nations communities earned him an honorary membership in the Stoney Indian Band (1972) and the title "Medicine Chief".

The Induction Ceremony, to be hosted for the first time in Calgary, will be held at BMO Centre on April 13, 2010. Joining Dr. Cochrane will be the other 5 inductees including Dr. Alan C. Burton MBE, Dr. Phil Gold CC OQ, Dr. James C. Hogg OC, Dr. Vera Peters OC and Dr. Calvin R. Stiller CM OOnt. The Canadian Medical Hall of Fame was created to tribute Canada's medical pioneers who, through discovery and innovation, have contributed to better health in Canada and the world.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our vision to be a leader in the research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including

atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

For further information please contact:

Theresa Kennedy
VP, Corporate Communications
Resverlogix Corp.
Phone: 403-254-9252
Fax: 403-256-8495
Email: Theresa@resverlogix.com

Sarah Zapotichny
Manager, Investor Relations
Resverlogix Corp.
Phone: 403-254-9252
Fax: 403-256-8495
Email: Sarah@resverlogix.com